Tang Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Tang Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300,000	Closed	-$8.01M	–	52
2025 Q4	$8.01M	Sell	300,000 -1,200,000	-80%	-$28.7M	0.4%	47
2025 Q3	$32M	Hold	1,500,000	–	–	1.23%	24
2025 Q2	$32.4M	Hold	1,500,000	–	–	1.64%	14
2025 Q1	$24.9M	Hold	1,500,000	–	–	1.38%	17
2024 Q4	$27.5M	Hold	1,500,000	–	–	1.82%	13
2024 Q3	$23.1M	Hold	1,500,000	–	–	1.65%	16
2024 Q2	$24.4M	Buy	1,500,000 +981,100	+189%	+$15.8M	2.48%	9
2024 Q1	$9.59M	Buy	518,900 +404,500	+354%	+$10M	1%	35
2023 Q4	$3.58M	Buy	114,400 +14,400	+14%	+$344K	0.33%	71
2023 Q3	$2.08M	Buy	+100,000	New	+$2.72M	0.29%	69

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Tang Capital Management's ACAD Position: Q1 2026 in Review

Tang Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 300,000 shares — an estimated $8.01M sold.

Tang Capital Management first reported a position in ACAD in Q3 2023 and held it in 10 quarters. The position peaked at $32.4M in Q2 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Tang Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Tang Capital Management sold 300,000 Acadia Pharmaceuticals shares in Q1 2026, an estimated $8.01M.
Tang Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 10 quarters.
Tang Capital Management's Acadia Pharmaceuticals position peaked at $32.4M in Q2 2025.
343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.